Trials / Completed
CompletedNCT01111240
Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis in Normal Medical Practice
A Long Term Documentation to Demonstrate Long Term Efficacy and Safety of Humira® in Patients With Psoriatic Arthritis Under Conditions of Daily Practice
- Status
- Completed
- Phase
- —
- Study type
- Observational
- Enrollment
- 4,635 (actual)
- Sponsor
- AbbVie (prior sponsor, Abbott) · Industry
- Sex
- All
- Age
- 18 Years
- Healthy volunteers
- Not accepted
Summary
This study is a documentation of effectiveness and safety of Humira in patients with psoriatic arthritis.
Detailed description
Psoriatic Arthritis participants receiving adalimumab are evaluated in a prospective, non-interventional study (NIS) for 2 years. Patients receive adalimumab 40 mg every other week (eow), per its label. Efficacy and safety parameters are measured routinely at baseline and after 3, 6, 9, 12, 18 and 24 months.
Conditions
Timeline
- Start date
- 2005-08-01
- Primary completion
- 2013-12-01
- Completion
- 2013-12-01
- First posted
- 2010-04-27
- Last updated
- 2014-12-30
- Results posted
- 2014-12-30
Locations
509 sites across 1 country: Germany
Source: ClinicalTrials.gov record NCT01111240. Inclusion in this directory is not an endorsement.